Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies…

Read More

Cancers 2020 September 25 [Link] Wei Song, Hao Wang, Minmin Lu, Xinxin Ni, Nacef Bahri, Shuihao Zhu, Limin Chen, Yuehong Wu, Jieqiong Qiu, Jonathan A Fletcher, Wen-Bin Ou Abstract Malignant mesothelioma is a locally aggressive and highly lethal neoplasm. Dysregulation and activation of Gas6/AXL tyrosine kinase signaling are associated with mesothelioma progression, but the mechanisms…

Read More

Annals of Oncology 2020 September 22 [Link] S Popat, A Curioni-Fontecedro, U Dafni, R Shah, M O’Brien, A Pope, P Fisher, J Spicer, A Roy, D Gilligan, O Gautschi, E Nadal, W D Janthur, R López Castro, R García Campelo, S Rusakiewicz, I Letovanec, V Polydoropoulou, H Roschitzki-Voser, B Ruepp, A Gasca-Ruchti, S Peters, R…

Read More

Journal of Immunology 2020 September 18 [Link] Mikihiro Kohno, Junichi Murakami, Licun Wu, Mei-Lin Chan, Zhihong Yun, B C John Cho, Marc de Perrot Abstract Increasing evidence indicates that local hypofractionated radiotherapy (LRT) can elicit both immunogenic and immunosuppressive local and systemic immune responses. We thus hypothesized that blockade of LRT-induced immunosuppressive responses could augment…

Read More

Cancer 2020 September 1 [Link] Raffit Hassan, Christine Alewine, Idrees Mian, Anna Spreafico, Lillian L Siu, Carlos Gomez-Roca, Jean-Pierre Delord, Antoine Italiano, Ulrik Lassen, Jean-Charles Soria, Rastilav Bahleda, Anish Thomas, Seth M Steinberg, Cody J Peer, William D Figg, Gerhard Niederfellner, Valérie Méresse Naegelen, Ira Pastan Abstract Background: LMB-100 is an antibody-toxin conjugate with an…

Read More

Cancers 2020 August 17 [Link] Haitang Yang, Duo Xu, Zhang Yang, Feng Yao, Heng Zhao, Ralph A Schmid, Ren-Wang Peng Abstract Background: Malignant pleural mesothelioma (MPM) is driven by the inactivation of tumor suppressor genes (TSGs). An unmet need in the field is the translation of the genomic landscape into effective TSG-specific therapies. Methods: We…

Read More

Current Drug Targets 2020 July 18 [Link] Lei Cheng, Li Na, Xiao-Ling Xu, Wei-Min Mao Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or…

Read More

Lung Cancer 2020 June 21 [Link] Luca Cantini, Federica Pecci, Alberto Murrone, Marco Tomasetti, Cecilia Copparoni, Ilaria Fiordoliva, Francesca Morgese, Silvia Rinaldi, Paola Mazzanti, Corrado Rubini, Alessia Cimadamore, Francesca Barbisan, Riccardo Giampieri, Marina Scarpelli, Lory Santarelli, Rossana Berardi Abstract Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is…

Read More

European Journal of Cardiothoracic Surgery 2020 May 25 [Link] Isabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau, Philippe Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen, Charlotte De Bondt, Dirk De Ruysscher, Valerie Durieux, Corinne Faivre-Finn, Dean A Fennell, Francoise Galateau-Salle, Laurent Greillier, Mir Ali Hoda, Walter Klepetko, Aude Lacourt, Phil McElnay,…

Read More